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Introduction
============

3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have been widely used as a lipid-lowering therapy in the primary and secondary prevention of atherosclerotic cardiovascular disease \[[@REF1]-[@REF3]\]. A recent analysis of the National Health and Nutrition Examination Survey (NHANES) described that prescription of cholesterol-lowering drugs increased with age from 17.4% in adults aged 40-59 to 47.6% in adults aged 75 years and older during 2011-2012. Moreover, among adults prescribed cholesterol-lowering medication, 83% used a statin alone \[[@REF4]\].

Although the precise mechanism of statin therapy on 25(OH)D metabolism is not fully clarified, researchers have postulated that since 7-dehydrocholesterol is the common precursor of vitamin D and cholesterol, the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase may increase 7-dehydrocholesterol levels providing an adequate substrate for the synthesis of 25-hydroxyvitamin D \[25(OH)D\] \[[@REF5]\]. The occupation of the active site of the CYP3A4 enzyme by statins may also account for increased serum 25(OH)D levels \[[@REF6]\]. Previously, few observational studies and randomized controlled trials reported conflicting results regarding the effect of statins on 25(OH)D concentrations. Some studies described higher 25(OH)D concentrations among statin users, whereas others did not \[[@REF7]-[@REF15]\]. Nevertheless, these studies were limited by small sample size, subjects with acute coronary syndrome, individual generic statins, diabetics hospitalized, and postmenopausal women with osteopenia \[[@REF7],[@REF9],[@REF11],[@REF14]-[@REF15]\]. Therefore, the purpose of this study was to examine the relationship between statin use and 25(OH)D concentrations in a nationally representative sample of older adults.

Materials and methods
=====================

The NHANES is a biannual cross-sectional study conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention. The purpose of the NHANES is to collect data about the health, nutritional status, and health behaviors of the noninstitutionalized civilian resident population of the U.S. Information about the analysis and reporting guidelines of the NHANES are described elsewhere \[[@REF16]\].

Characteristics of participants

The demographics file provides individual, family, and household level information on the following topics: The six-month time period when the examination was performed, demographic information about the household reference person, and other selected demographic information, such as gender, age, race/Hispanic origin, and education. The Department of Health and Human Services guidelines were used as the poverty measure to calculate the ratio of family income to poverty. 

In the Mobile Examination Center, BMI was calculated as body weight in kilograms divided by height in meters squared and then rounded to one decimal place. Questionnaires on alcohol consumption and cigarette smoking were also administered. As previously reported, the physical activity questionnaire is based on the Global Physical Activity Questionnaire and includes questions related to leisure-time activities. The reported number of days and time (in minutes) spent performing vigorous or moderate leisure-time physical activity in the previous week were calculated, and according to the 2008 Physical Activity Guidelines for Americans, participants were categorized as physically active, insufficiently active, or physically inactive \[[@REF17]\]. Moreover, participants were asked about their general health, which was categorized as good to excellent and fair to poor. The diagnosis of diabetes was established if participants reported a physician diagnosis of diabetes or had an HbA~1c~ ≥6.5% \[[@REF18]\]. Cardiovascular disease was defined based on an affirmative response to any one of four questions about doctor-diagnosed heart attack, angina, coronary heart disease, or stroke \[[@REF4]\]. Similarly, participants were considered to have high cholesterol if they affirmatively responded to the question "Have you ever been told by a doctor or other health professional that your blood cholesterol level was high?"

Vitamin D intake

Since the NHANES cycle 2007-2008, vitamin D intake has been collected from the types and amounts of foods and beverages consumed during the 24-hour period prior to the interview. All NHANES participants responding to the dietary recall interview were also eligible for the dietary supplement questions. The participant's use of vitamin D supplements was reported as a mean vitamin D dosage over the course of 30 days prior to the household interview. Data were routinely examined for discrepancies and erroneous entries \[[@REF19]\].

25(OH)D and its Metabolite Concentrations

The CDC developed the standardized liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure 25(OH)D~3~, 25(OH)D~2~, and total 25(OH)D levels. For the LC-MS/MS method, total 25(OH)D (in SI units of nmol/L) was defined as the sum of 25(OH)D~3~ and 25(OH)D~2~. However, due to rounding off, the sum of 25(OH)D~3~ and 25(OH)D~2~ will not necessarily be equal to the 25(OH)D. This method has better analytical specificity and sensitivity compared to immunoassay methods and fixed analytical goals for imprecision (≤10%) and bias (≤5%) \[[@REF20]\].

Statin prescription

During the household interview, participants were asked if they have taken medications in the past 30 days for which they needed a prescription. Those who answer "yes" were asked to show the interviewer the medication containers of all the products used. For each drug reported, the interviewer recorded the product's complete name from the container. Prescription medications were classified based on the three-level nested therapeutic classification scheme of Cerner Multum's Lexicon. Cholesterol-lowering medications were identified using the second level of drug category code 19, and the third level of drug category code 173 was used to identify statins \[[@REF4]\]. The following drugs were included in the present analysis: lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, and pitavastatin.

Statistical analysis

The characteristics of the study population were stratified according to statin therapy and compared using the chi-squared test and the t-test for categorical and continuous variables, respectively. General linear models adjusted for the six-month study period, age, gender, race/ethnicity, education, income, BMI, smoking status, alcohol use, physical activity, self-reported health status, diabetes, and vitamin D intake were created to compare 25(OH)D~2~, 25(OH)D~3~, and total 25(OH)D concentrations between statin users with their non-user counterparts. Similarly, the independent associations between generic statins, the duration of statin therapy (\< 2, 3-6, and \>6 years) and 25(OH)D concentrations were explored. Since a small number of participants (n = 5) were prescribed fluvastatin, cerivastatin, or pitavastatin, these drugs were excluded from this analysis. Moreover, in subgroup analyses, the modifying effects of BMI categories and vitamin D intake (\< 400, 400-800, and \>800 IU) on 25(OH)D levels were examined according to statin therapy status. Statistical analyses were performed using SPSS Complex Sample software, V.17 (SPSS Inc, Chicago, Illinois, USA) to incorporate constructed weights for the combined survey cycles and obtain unbiased, national estimates representative of the older U.S. population. A P-value \<0.05 was considered statistically significant. Of 7,859 participants aged 60 years and older in the NHANES cycles 2007-2008 through 2013-2014, those with missing data on 25(OH)D concentrations (n = 990), BMI (n = 514), and dietary vitamin D (n = 945) were excluded from the analysis. In general, participants with missing data were more likely to be examined during the winter months, female, had less than high school education, physically inactive, and self-reported fair to poor health.

Results
=======

A total of 6,261 participants with a mean age of 69.5 years comprised the sample size. Of these, 40.2% reported used statins and the median duration of therapy was 5 years. Table [1](#TAB1){ref-type="table"} shows the characteristics of participants stratified according to statin therapy. Overall, statin therapy was higher in men, non-Hispanic whites, high-school graduates, former smokers, and those with fair to poor health compared with those who did not. Moreover, as expected, statins were more frequently prescribed among diabetics and those with cardiovascular disease. In general, mean 25(OH)D~2~ and total 25(OH)D concentrations were significantly higher among statin users than their non-user counterparts. 

###### Characteristics of the participants according to statin therapy

RIP, Ratio of family income to poverty; AA, Associates of Arts  

Parenthesis represents standard error of the estimates.

  ----------------------------- --------------------------- ------------------------ ----------
                                Statin users  (n = 2,456)   Non-users  (n = 3,805)   P value
  Six-month period, %                                                                0.816
   Nov 1^st^ to Apr 30^th^      38.7 (3.4)                  38.3 (3.4)                
   May 1^st^ to Oct 31^th^      61.3 (3.4)                  61.7 (3.4)                
  Age (years), mean             70.4 (0.2)                  69.0 (0.1)               \<0.0001
  Gender, %                                                                          \<0.0001
   Male                         51.0 (1.1)                  42.0 (0.8)                
   Female                       49.0 (1.1)                  58.0 (0.8)                
  Race/ethnicity, %                                                                  \<0.05
   Hispanics                    6.2 (0.9)                     7.8 (1.0)               
   Non-Hispanic white           81.1 (1.3)                  80.3 (1.5)                
   Non-Hispanic black             7.7 (0.8)                   8.0 (0.8)               
   Others                         5.0 (0.6)                   3.9 (0.4)               
  BMI (kg/m^2^), mean           29.8 (0.1)                  28.4 (0.1)               \<0.0001
  Education, %                                                                       \<0.05
   Less than high school        21.8 (1.5)                  19.4 (1.2)                
   High school graduate         25.7 (1.4)                  22.4 (0.9)                
   Some college or AA degree    28.4 (1.4)                  29.1 (1.0)                
   College graduate or above    24.1 (1.4)                  29.1 (1.6)                
  RIP, %                                                                             0.101
  \<1.00                          8.6 (0.7)                   9.7 (0.6)               
  ≥1.00                         91.4 (0.7)                  90.3 (0.6)                
  Smoking status, %                                                                  0.0001
   Never                        45.2 (1.5)                  51.7 (1.1)                
   Former                       44.5 (1.4)                  37.5 (0.9)                
   Current                      10.8 (0.7)                  10.8 (0.7)                
  Alcohol use, %                                                                     0.470
   Yes                          70.1 (1.4)                  69.0 (1.4)                
   No                           29.9 (1.4)                  31.0 (1.4)                
  Physical activity status, %                                                        0.342
   Inactive                     56.3 (1.6)                  56.6 (1.4)                
   \<150 min/week               14.7 (0.9)                  16.2 (0.8)                
   ≥150 min/week                29.0 (1.4)                  27.2 (1.3)                
  General health condition, %                                                        \<0.05
   Good to excellent            75.6 (1.2)                  80.2 (0.9)                
   Fair to poor                 24.4 (1.2)                  19.8 (0.9)                
  Diabetes, %                                                                        \<0.0001
   Yes                          33.2 (1.2)                  15.9 (0.9)                
   No                           66.8 (1.2)                  84.1 (0.9)                
  High cholesterol, %                                                                \<0.0001
   Yes                          82.2 (0.9)                  38.9 (1.1)                
   No                           17.8 (0.9)                  61.1 (1.1)                
  Cardiovascular disease, %                                                          \<0.0001
   Yes                          66.0 (1.8)                  34.0 (1.8)                
   No                           33.7 (1.0)                  66.3 (1.0)                
  Vitamin D intake (IU), %                                                           \<0.05
   \<400                        43.5 (1.4)                  48.5 (0.9)                
   400-800                      22.1 (0.9)                  21.2 (1.1)                
   \>800                        34.4 (1.2)                  30.3 (1.1)                
  25(OH)D (nmol/L), mean                                                              
   Total 25(OH)D                79.0 (1.0)                  75.4 (0.8)               \<0.05
   25(OH)D~3~                   71.5 (1.0)                  69.8 (0.9)                0.081
   25(OH)D~2~                     7.5 (0.7)                   5.6 (0.4)              \<0.05
  ----------------------------- --------------------------- ------------------------ ----------

As shown in Table [2](#TAB2){ref-type="table"}, after adjustment for potential confounders, 25(OH)D~3~ and 25(OH)D levels were on average 3.1 and 4.4 nmol/L higher among older adults taking statins than those who did not, respectively. In contrast, a non-significant 1.4 nmol/L difference in 25(OH)D~2~ levels was seen among older adults on statin therapy. 

###### The association between statin therapy and 25(OH)D levels and its metabolites among older adults

Model 1 adjusted for study period, age, gender, race/ethnicity, education, income, BMI, smoking status, alcohol use, and physical activity.

Model 2 adjusted for model 1 and self-reported health status, diabetes, and vitamin D intake.

  -------------------------- ------------------- ---------------- ---------------------- ----------
  Vitamin D concentrations   Statin users (SE)   Non-users (SE)   Mean difference (SE)   P-value
  25(OH)D~3~ (nmol/L)                                                                     
  Mean                       71.5 (1.0)          69.8 (0.9)       1.7 (0.9)              0.081
  Model 1                    72.9 (0.9)          69.1 (0.8)       3.8 (0.9)              \<0.0001
  Model 2                    72.4 (0.8)          69.3 (0.7)       3.1 (0.8)              \<0.05
  25(OH)D~2~(nmol/L)                                                                      
  Mean                       7.5 (0.7)           5.6 (0.4)        1.9 (0.6)              \<0.05
  Model 1                    7.5 (0.7)           5.7 (0.4)        1.8 (0.6)              \<0.05
  Model 2                    7.2 (0.7)           5.8 (0.4)        1.4 (0.6)              0.054
  Total 25(OH)D (nmol/L)                                                                  
  Mean                       79.0 (1.0)          75.4 (0.8)       3.6 (1.0)              \<0.05
  Model 1                    80.5 (1.0)          74.8 (0.7)       5.7 (0.9)              \<0.0001
  Model 2                    79.6 (0.8)          75.2 (0.7)       4.4 (1.0)              \<0.0001
  -------------------------- ------------------- ---------------- ---------------------- ----------

As shown in Figure [1](#FIG1){ref-type="fig"}, adjusted mean 25(OH)D concentrations were consistently higher among older adults taking statins irrespective of the duration of treatment. For instance, those taking statins \>6 years had on average 6.2 nmol/L higher 25(OH)D concentrations than those who did not. 

![25(OH)D concentrations according to duration of statin therapy among older adults](cureus-0012-00000008950-i01){#FIG1}

As shown in Figure [2](#FIG2){ref-type="fig"}, overall higher 25(OH)D concentrations were consistently seen among participants on any generic statin therapy. However, these associations were statically significant among subjects taking simvastatin, atorvastatin, or rosuvastatin. 

![25(OH)D concentrations according to generic statin therapy among older adults](cureus-0012-00000008950-i02){#FIG2}

As shown in Figure [3](#FIG3){ref-type="fig"}, 25(OH)D concentrations progressively increased with an increase in vitamin D intake. However, no significant differences in 25(OH)D levels were seen between statin users compared with their non-user counterparts, particularly among participants taking vitamin D between 400 and 800 IU and \>800 IU per day. 

![25(OH)D concentrations according to statin therapy and vitamin D intake](cureus-0012-00000008950-i03){#FIG3}

As expected, 25(OH)D concentrations were inversely correlated with BMI categories. Despite this evidence, higher 25(OH)D levels were seen among normal-weight, overweight, and obese participants on statin therapy than those who did not (Figure [4](#FIG4){ref-type="fig"}). 

![25(OH)D concentrations according to statin therapy and BMI categories\
BMI, body mass index](cureus-0012-00000008950-i04){#FIG4}

Discussion
==========

The present findings indicate that serum 25(OH)~3~ and total 25(OH)D concentrations were significantly higher among statin users than their non-user counterparts. Notably, these associations were consistently seen after adjustment for potential confounders, irrespective of the duration of therapy, or generic statin prescribed. Our findings contrast with those from a recent systematic review and meta-analysis conducted by Mazidi *et al*., in which inconclusive effects of statins on 25(OH)D concentrations were reported. Indeed, the pooled estimate (weighted mean difference) of the effect of statin therapy on serum vitamin D from randomized clinical trials was 2.71 ng/ml and decreased by -0.70 ng/ml in observational studies. These contradictory findings were attributed to small sample sizes of the included studies and different doses and duration of vitamin D supplementation \[[@REF5]\].

In subgroup analyses, we found that among participants with dietary vitamin D intakes between 400 and 800 IU or \>800 IU per day, 25(OH)D concentrations did not significantly differ between participants on statin therapy and those who did not. However, increased 25(OH)D levels were seen among older adults on statin therapy and a daily intake of \<400 IU per day. Since dietary vitamin D intake from food and supplements is the main determinant of vitamin D status in older adults, increased 25(OH)D levels among statin users were particularly seen among those with inadequate vitamin D intake \[[@REF21]\]. In addition, Bischoff-Ferrari *et al*. in a pooled analysis of three double-blind randomized clinical trials suggested that lower 25(OH)D response to vitamin D supplementation may be a class effect of all statins, which differ according to vitamin D dosing regimens \[[@REF13]\]. 

Notably, higher 25(OH)D concentrations were consistently seen among statin users, irrespective of the duration of therapy. Moreover, mean 25(OH)D concentrations minimally differed between statin therapy \<2 years compared with their counterparts with \>6 years. Thus, the present findings suggest that statins have a sustained effect on 25(OH)D levels, which was seen even at the beginning of therapy. Similarly, higher 25(OH)D concentrations were seen among participants according to individual generic statins use. This association was statistically significant among participants taking simvastatin, atorvastatin, or rosuvastatin. Indeed, subjects taking simvastatin and atorvastatin, the most frequently prescribed statins, had on average 5.2 and 3.7 nmol/L higher 25(OH)D levels compared with non-users, respectively. In contrast, Renjmark *et al*. in a small randomized controlled trial among healthy postmenopausal women reported no significant differences in plasma 25(OH)D levels between subjects treated with simvastatin 40 mg/day for a year compared with their counterparts receiving placebo \[[@REF15]\]. Likewise, Mazidi *et al*. previously demonstrated in a randomized, double-blind, placebo-controlled trial lasting 30 days that simvastatin 40 mg/day did not have a significant effect on serum 25(OH)D levels \[[@REF7]\]. Possible explanations for these contradictory results were attributed to unmeasured predictors of vitamin D status such as vitamin D intake and sun exposure \[[@REF15]\]. Lower 25(OH)D concentrations have been consistently reported across different latitudes in obese subjects compared with their normal-weight counterparts, which have been related to limited sun exposure, decreased bioavailability of vitamin D in fat tissue, and lower vitamin D supplements use \[[@REF22]-[@REF25]\]. As expected, the present results also demonstrated an inverse relationship between BMI and 25(OH)D concentrations among older adults. Despite this evidence, normal-weight, overweight, and obese participants taking statins had significantly higher 25(OH)D concentrations than those who did not. 

Of relevance, the beneficial effects of statin therapy on coronary artery disease have been described as not only aggressive reduction of circulating pro-atherogenic lipid particles but also to its pleiotropic effects, including improvement of endothelial function and anti-inflammatory and anti-oxidant actions, whose mechanism is presently undetermined \[[@REF26]\]. Moreover, it has been postulated that the pleiotropic effects of statins may be mediated by vitamin D \[[@REF9]\]. In fact, in agreement with this hypothesis, previous studies have demonstrated that lower 25(OH)D concentrations have been inversely associated with the progression of aortic calcification and myocardial infarction \[[@REF27]-[@REF28]\]. 

The present study has several limitations that should be mentioned. First, because of the NHANES cross-sectional design, these results do not necessarily infer causation. Second, the statin dosage was not available in the prescription medication section. Thus, the intensity of statin therapy on 25(OH)D concentrations may not be established. Third, sun exposure and sun-protective behavior characteristics, which may have a direct effect on the synthesis of 25(OH)D~3~, were not explored in the present analysis. Fourth, most sociodemographic and health variables were self-reported, which may have led to recall bias. Despite these limitations, this study clearly demonstrated that statin therapy is associated with increased 25(OH)D concentrations in a large nationally representative sample of older adults.

Conclusions
===========

Older adults on statin therapy had significantly higher 25(OH)D concentrations than those who did not. Further research is needed to precisely define the mechanism of this association and determine whether the pleiotropic effects attributed to statins may be mediated by vitamin D.
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